Poprotskiy Alexey / Shutterstock.com
Teva has reached a settlement in its patent battle with two pharmaceutical companies, ending all litigation over its ProAir HFA (albuterol sulfate) inhalation aerosol.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Teva, Perrigo, Catalent, patent, ProAir HFA
